New heart monitor could spot hidden danger after valve surgery

NCT ID NCT02153307

Recruiting now Diagnosis Sponsor: Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a small implantable heart monitor (Reveal LINQ) can detect serious heart block in people who develop a new electrical problem (left bundle branch block) after having their aortic valve replaced (TAVI). About 80 participants will get the monitor and be followed for up to 2 years. The goal is to see how often dangerous heart block occurs and whether the monitor helps doctors make better treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Reveal LINQ® insertable cardiac monitor (implantable device)
What this could lead to: If successful, this could show that long-term heart monitoring helps catch dangerous heart rhythm problems early in TAVI patients, potentially preventing fainting or sudden cardiac arrest.
What could go wrong: This is a small, early-stage observational study (80 participants) with no control group. The device may detect harmless events that lead to unnecessary worry or procedures. Results may not apply to all TAVI patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC VALVE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Aortic Valve Disease aortic valve disorder cardiac conduction defect

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AORTIC VALVE DISEASE CONDUCTION DISTURBANCES

Contacts and locations

Locations

IUCPQ
RECRUITING

Québec, Quebec, G1V 4G5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.